Nordic NASH Symposium
PanNASH speaker; Dr. Stephen Harrison takes part in the Nordic NASH symposium which aims to discuss management and diagnosis strategies of improving outcomes for patients with non-alcoholic steatohepatitis (NASH)
PanNASH speaker; Dr. Stephen Harrison takes part in the Nordic NASH symposium which aims to discuss management and diagnosis strategies of improving outcomes for patients with non-alcoholic steatohepatitis (NASH)
A discussion about the clinical evidence on all-cause and specific mortality of MAFLD.
The authors aimed to examine the impact of HTN on survival outcomes in a longitudinal cohort of NAFLD patients.
The authors investigated the prognostic implication of the FIB-4 index regarding right ventricular dysfunction in patients with HFpEF.
Our growing understanding of the natural history and pathogenesis of MAFLD and the predominant role of metabolic dysfunction in this disease have evoked efforts to redefine fatty liver disease.
The identification of high-risk MAFLD patients is paramount. Liver biopsy is still considered the gold standard for the assessment of patients with MAFLD. The search for noninvasive biomarkers .....
In this study, F. Barrow et al. (University of Minnesota Medical School, Minneapolis, USA) report that NASH livers accumulate B cells with elevated pro-inflammatory cytokine secretion .....
In this article, P. M. Abuja et al. (Medical University of Graz, Austria) propose that steatohepatitis develops in four phases with transitions, priming triggering, adaptation....
The American Gastroenterological Association assembled a multidisciplinary panel of experts to develop a Clinical Care Pathway providing explicit guidance on the.....